Alejandro Luna
A5080522770- CAR-T cell therapy research
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immune Cell Function and Interaction
- Biomedical Ethics and Regulation
- Integrated Circuits and Semiconductor Failure Analysis
- Silicon Carbide Semiconductor Technologies
- Acute Lymphoblastic Leukemia research
- HER2/EGFR in Cancer Research
- Virus-based gene therapy research
- Lung Cancer Treatments and Mutations
- COVID-19 and healthcare impacts
- Viral Infectious Diseases and Gene Expression in Insects
- Advancements in Semiconductor Devices and Circuit Design
- Click Chemistry and Applications
- Pancreatic function and diabetes
- Mesenchymal stem cell research
- Kruppel-like factors research
- Hematological disorders and diagnostics
- Blood transfusion and management
Memorial Sloan Kettering Cancer Center
2023-2025
Hospital Universitario Ramón y Cajal
2019-2025
Instituto Ramón y Cajal de Investigación Sanitaria
2020-2025
Kettering University
2023-2024
Universidad de Alcalá
2022
Universidad Autónoma de Coahuila
2015
Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined.This was a Spanish transplant group cell therapy (GETH) multicenter retrospective observational study, which included large cohort blood cancer laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020.We 367 pediatric adult malignancies, including recipients autologous (ASCT) (n = 58) or allogeneic stem transplantation (allo-SCT) 65) 41...
Failure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in patients with chronic myeloid leukemia (CML). Asciminib, recently approved by the US Federal Drug Administration, has demonstrated clinical trials good efficacy and safety profile after failure 2GTKI. However, no study specifically addressed response rates to asciminib ponatinib pretreated (PPT). Here, we present data on responses from 52 practice, 20 them (38%) prior exposure. We analyzed...
(1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction asciminib may be promising option intolerant patients, as it is first-in-class inhibitor more selective mechanism action different from ATP-competitive inhibition that occurs Therefore, our goal was to analyze toxicities shown well study cross-toxicity previous (2) Methods: An observational,...
<p>Supplementary Figure 3. Kaplan-Meier survival curves for OS and PFS. Comparisons include (A) (B) PFS CD4 <155 !155 CD4+ T cell counts above below the median day 30 metric of 155 cells/μL. P-values are derived from multivariate Cox proportional hazards model stratified by CAR-T product adjusted confounders, including pre-CAR-T age, LDH pre-lymphodepletion, bridging.</p>
<p>Supplementary Figure 5. Gating strategy for the TBNK assay. (A) FSC vs SSC dot plot was used to identify debris, characterized as low and FSC. Non-debris events are subsequent gating. (B) Using a FSC-A FSC-H plot, singlet gate isused include remove doublet events. (C) Singlet in CD45 is set around CD45+ lymphocyte events, by bright CD45. (D) arethen passed through CD3 CD19 CD19+ B cells CD3+ T cells. (E) further identified CD3+CD4+ helper CD3+CD8+ cytotoxic CD4 CD8 plot. (F)...
<div>Abstract<p>Patients treated with chimeric antigen receptor T-cell (CAR-T) therapy are subject to profound immunosuppression. Dynamics of immune reconstitution (IR) and impacts IR on outcomes following infusion across CAR-T products not well understood. In this study, we profiled in 263 patients relapsed/refractory large B-cell lymphoma receiving (axicabtagene ciloleucel 44.9%, lisocabtagene maraleucel 30.4%, tisagenlecleucel 24.7%). Following infusion, remain persistently...
<p>Supplementary Figure 2. Boxplots with superimposed dot plots demonstrate immune subset distributions at clinically significant timepoints, including days 30, 100, 180, and 365 post-CAR-T. Axi-cel in highlighted blue, liso-cel green, tisa-cel red. Subsets shown are (A) CD4+CCR7-45RA+ effector cells, (B) CD4+CCR7+45RA+ naïve (C) CD4+CCR7+45RA- CM (D) CD8+CCR7+45RA+ (E) CD8+CCR7-45RA+ TEMRA (F) CD8+CCR7-45RA- EM (G) CD8+CCR7+45RA- cells. Ranges of 20 to 45, 80 120, 150 210, 300 400...
<p>Supplementary Figure 1. Immune subset trajectories from time of CAR-T (time 0) through one year 365) following with superimposed boxplots at predefined time-points. Subsets include (A) CD3+ T cells, (B) CD3-19+ B (C) CD3-56+16+ NK (D) CD4+ (E) CD4+CCR7-45RA- EM (F) CD4+CCR7-45RA+ effector (G) CD4+CCR7+45RA- CM (H) CD4+CCR7+45RA+ naïve (I) CD8+ (J) CD8+CCR7-45RA- (K) CD8+CCR7-45RA+ TEMRA (L) CD8+CCR7+45RA- and (M) CD8+CCR7+45RA+ cells. Trajectories depicted are estimated using LOESS...
<p>Supplementary Figure 7. Gating strategy for the T regulatory cells assay. (A, B) CD3+CD4+ helper are passed through a CD25 vs CD127 dot plot to identify CD4+CD127-CD25+ cells, and (C) CCR4 CCR4+CD25+ cells. defined as CD4+CD127-CCR4+CD25+ via series of AND gates.</p>
<p>Supplementary Figure 4. Hazard ratios for OS (in blue) and PFS red) derived from (A) unadjusted Cox proportional hazards models, (B) models stratified by CAR-T product, (C) both product adjusted confounders, including pre-CAR-T age, LDH pre- lymphodepletion, bridging. Each landmark time on the X-axis represents at which are landmarked. For instance, hazard corresponding to 35 utilizes day 20 metrics (using latest measurement within pre-specified range of days 10–35). Similarly, 75...
<p>Supplementary Figure 6. Gating strategy for the T cell subsets assay. (A, B) CD3+CD4+ helper cells are passed through a CCR7 vs CD45RA dot plot to identify CD4+CCR7+CD45RA+ naïve cells, CD4+CCR7+CD45RA- central memory (CM) CD4+CCR7-CD45RA- effector (EM) and CD4+CCR7-CD45RA+ cells. (C, D) Similarly, CD3+CD8+ cytotoxic CD8+CCR7+CD45RA+ CD8+CCR7+CD45RA- CM CD8+CCR7-CD45RA- EM CD8+CCR7-CD45RA+ (TEMRA) cells.</p>
Abstract The role of extranodal (EN) sites as potential sanctuary regions resistant to CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in large B-cell lymphoma (LBCL) remains unclear. To investigate this, we retrospectively analyzed 283 adults treated with commercial CD19 CAR-T therapy, assessing 958 PET-CT scans across four time points: pre-apheresis, pre-lymphodepletion, best response, and relapse. EN involvement prior was common (76%). Outcomes for patients exclusive...
Abstract Background During the COVID‐19 outbreak, most hospitals deferred elective surgical procedures to allow space for overwhelming number of patient admissions, expecting a decrease in routine blood component requirements. However, because transfusion support needs patients are not well known, its impact on hospital supply is uncertain. The objective this study was assess effect pandemic demand. Study Design and Methods Transfusion records during peak (March 1‐April 30, 2020) were...
BCR-ABL is an aberrant tyrosine kinase responsible for chronic myeloid leukemia (CML). Tyrosine inhibitors (TKIs) induce a potent antileukemic response mostly based on the inhibition of BCR-ABL, but they also increase activity Natural Killer (NK) and CD8+ T cells. After several years, patients may interrupt treatment due to sustained, deep molecular response. By unknown reasons, half relapse during interruption, whereas others maintain control residual leukemic cells years. In this study,...